What this study adds
Our study found that mirtazapine use for patients affected by major depressive disorder may increase the risk of hypothyroxinemia.
The finding of increased risk of developing hypothyroxinemia after mirtazapine treatment has significant clinical implication. Clinicians should be aware that thyroid function insufficiency may be ignored in patients treated by mirtazapine due to attention paid only to those with elevated TSH and failure to recognize hypothyroxinemia.